New therapies for hepatocellular carcinoma

[1]  M. Arsura,et al.  Nuclear factor-κB and liver carcinogenesis , 2005 .

[2]  D. Schuppan,et al.  Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor. , 2005, Journal of hepatology.

[3]  M. Manns,et al.  Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma , 2005, Hepatology.

[4]  Yusuke Nakamura,et al.  Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. , 2005, Cancer research.

[5]  D. Min,et al.  Hepatitis B virus X protein represses E-cadherin expression via activation of DNA methyltransferase 1 , 2005, Oncogene.

[6]  Michael Karin,et al.  IKK/NF-κB signaling: balancing life and death – a new approach to cancer therapy , 2005 .

[7]  C. Thompson,et al.  The survival kinases Akt and Pim as potential pharmacological targets. , 2005, The Journal of clinical investigation.

[8]  D. Schuppan,et al.  Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. , 2005, Journal of hepatology.

[9]  P. Philip,et al.  Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Osada,et al.  Evaluation of extracellular signal regulated kinase expression and its relation to treatment of hepatocellular carcinoma. , 2005, Journal of the American College of Surgeons.

[11]  Wei-Chen Lee,et al.  Vaccination of Advanced Hepatocellular Carcinoma Patients with Tumor Lysate-Pulsed Dendritic Cells: A Clinical Trial , 2005, Journal of immunotherapy.

[12]  M. Li‐Weber,et al.  Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL , 2005, Hepatology.

[13]  M. Abecassis,et al.  Use of yttrium‐90 microspheres (TheraSphere®) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: A case report , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[14]  J. Shay,et al.  In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. , 2005, Cancer research.

[15]  Jiri Zavadil,et al.  TGF-β and epithelial-to-mesenchymal transitions , 2005, Oncogene.

[16]  J. Prieto,et al.  Dendritic cells delivered inside human carcinomas are sequestered by interleukin‐8 , 2005, International journal of cancer.

[17]  Manuel Hidalgo,et al.  Intracellular signal transduction pathway proteins as targets for cancer therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. LoRusso,et al.  Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Zacharoulis,et al.  Antiangiogenic strategies in hepatocellular carcinoma: current status , 2005, Expert review of anticancer therapy.

[20]  J. Lyons,et al.  Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. , 2005, Current opinion in pharmacology.

[21]  Jun Qin,et al.  Erk Associates with and Primes GSK-3β for Its Inactivation Resulting in Upregulation of β-Catenin , 2005 .

[22]  E. Gelmann,et al.  The ubiquitin-proteasome pathway and its role in cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Tarin,et al.  Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? , 2005, Cancer research.

[24]  Alain Spatz,et al.  Cutaneous side-effects of kinase inhibitors and blocking antibodies. , 2005, The Lancet. Oncology.

[25]  G. Lozano,et al.  Gankyrin: an intriguing name for a novel regulator of p53 and RB. , 2005, Cancer cell.

[26]  Tomoko Masuda,et al.  The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. , 2005, Cancer cell.

[27]  H. Lien,et al.  Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma. , 2005, Cancer letters.

[28]  T. Sauerbruch,et al.  Effective angiostatic treatment in a murine metastatic and orthotopic hepatoma model , 2005, Hepatology.

[29]  J. Barrio,et al.  Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. , 2005, Gastroenterology.

[30]  V. Carloni,et al.  Farnesyltransferase Inhibitor, ABT-100, Is a Potent Liver Cancer Chemopreventive Agent , 2005, Clinical Cancer Research.

[31]  A. Ryan,et al.  ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity , 2005, British Journal of Cancer.

[32]  David C. Lee,et al.  Novel Role for Amphiregulin in Protection from Liver Injury* , 2005, Journal of Biological Chemistry.

[33]  Mark Peifer,et al.  Decisions, decisions: beta-catenin chooses between adhesion and transcription. , 2005, Trends in cell biology.

[34]  G. Gores,et al.  Hepatocellular carcinoma: molecular pathways and new therapeutic targets. , 2005, Seminars in liver disease.

[35]  S. Fan,et al.  Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. , 2005, Cancer research.

[36]  R. Schulte‐Hermann,et al.  Integration of Ras subeffector signaling in TGF-beta mediated late stage hepatocarcinogenesis. , 2005, Carcinogenesis.

[37]  Amie Y Lee,et al.  Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations , 2005, Oncogene.

[38]  Andrew Macdonald,et al.  Hepatitis C Virus NS5A-Mediated Activation of Phosphoinositide 3-Kinase Results in Stabilization of Cellular β-Catenin and Stimulation of β-Catenin-Responsive Transcription , 2005, Journal of Virology.

[39]  H. Clevers,et al.  Wnt signalling in stem cells and cancer , 2005, Nature.

[40]  J. Baselga,et al.  Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  D. Hedley,et al.  Raf kinase as a target for anticancer therapeutics , 2005, Molecular Cancer Therapeutics.

[42]  E. Raymond,et al.  mTOR-targeted therapy of cancer with rapamycin derivatives. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  Stefano Colagrande,et al.  Fibrosis in chronic liver diseases: diagnosis and management. , 2005, Journal of hepatology.

[44]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[45]  M. Choi,et al.  Local radiotherapy for patients with unresectable hepatocellular carcinoma. , 2005, International journal of radiation oncology, biology, physics.

[46]  N. Restifo,et al.  CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. , 2005, Journal of immunotherapy.

[47]  D. Hedley,et al.  Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. , 2005, Cancer research.

[48]  J. Prieto,et al.  Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  M. von Knebel Doeberitz,et al.  Wnt/β‐catenin‐pathway as a molecular target for future anti‐cancer therapeutics , 2005 .

[50]  Dirk Strumberg,et al.  Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  David C. Lee,et al.  Amphiregulin: an early trigger of liver regeneration in mice. , 2005, Gastroenterology.

[52]  W. Cacheux,et al.  Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis , 2005, Hepatology.

[53]  Michael F Clarke,et al.  Self-renewal and solid-tumor stem cells. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[54]  J. Dancey,et al.  Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. , 2005, Journal of vascular and interventional radiology : JVIR.

[55]  J. Dancey,et al.  Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. , 2005, Journal of vascular and interventional radiology : JVIR.

[56]  G. Nicolson,et al.  Focal adhesion kinase regulates metastatic adhesion of carcinoma cells within liver sinusoids. , 2005, The American journal of pathology.

[57]  M. Erion,et al.  Liver-Targeted Drug Delivery Using HepDirect1 Prodrugs , 2005, Journal of Pharmacology and Experimental Therapeutics.

[58]  A. G. de Herreros,et al.  Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription , 2005, The Journal of cell biology.

[59]  R. Sills,et al.  Overview of the Molecular Biology of Hepatocellular Neoplasms and Hepatoblastomas of the Mouse Liver , 2005, Toxicologic pathology.

[60]  M. Oshimura,et al.  PI3K-Akt pathway: Its functions and alterations in human cancer , 2004, Apoptosis.

[61]  S. Dedhar,et al.  Integrin-linked kinase: a cancer therapeutic target unique among its ILK , 2005, Nature Reviews Cancer.

[62]  T. Roskams,et al.  Early hepatocellular carcinoma and dysplastic nodules. , 2005, Seminars in liver disease.

[63]  S. Thorgeirsson,et al.  Genetic profiling of human hepatocellular carcinoma. , 2005, Seminars in liver disease.

[64]  C. Blobel,et al.  ADAMs: key components in EGFR signalling and development , 2005, Nature Reviews Molecular Cell Biology.

[65]  M. Pollak,et al.  Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells , 2005, Breast Cancer Research.

[66]  M. Torbenson,et al.  mTOR and P70 S6 Kinase Expression in Primary Liver Neoplasms , 2004, Clinical Cancer Research.

[67]  Yusuke Nakamura,et al.  Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). , 2004, Human molecular genetics.

[68]  D. Schuppan,et al.  Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. , 2004, Journal of hepatology.

[69]  M. Osanai,et al.  Oncogenic Raf-1 regulates epithelial to mesenchymal transition via distinct signal transduction pathways in an immortalized mouse hepatic cell line. , 2004, Carcinogenesis.

[70]  C. Nutting,et al.  Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. , 2004, International journal of radiation oncology, biology, physics.

[71]  S. Lowe,et al.  Intrinsic tumour suppression , 2004, Nature.

[72]  A. Paradiso,et al.  Laminin-5 offsets the efficacy of gefitinib (‘Iressa’) in hepatocellular carcinoma cells , 2004, British Journal of Cancer.

[73]  Y. Eguchi,et al.  Transforming growth factor‐β1‐induced apoptosis is blocked by β1‐integrin‐mediated mitogen‐activated protein kinase activation in human hepatoma cells , 2004, Cancer science.

[74]  S. Thorgeirsson,et al.  Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. , 2004, Gastroenterology.

[75]  Henk-Jan Guchelaar,et al.  Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. , 2004, Cancer treatment reviews.

[76]  Christian Bréchot,et al.  Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. , 2004, Gastroenterology.

[77]  T. Liang,et al.  Pathogenesis of hepatitis C-associated hepatocellular carcinoma. , 2004, Gastroenterology.

[78]  Josepa Ribes,et al.  Primary liver cancer: worldwide incidence and trends. , 2004, Gastroenterology.

[79]  M. Soulen,et al.  Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. , 2004, Gastroenterology.

[80]  Christopher H. Contag,et al.  MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer , 2004, Nature.

[81]  R. Taub.  Liver regeneration: from myth to mechanism , 2004, Nature Reviews Molecular Cell Biology.

[82]  D. Wolf,et al.  Endothelial progenitor cells: A source for therapeutic vasculogenesis? , 2004, Journal of cellular and molecular medicine.

[83]  Miran Kim,et al.  Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. , 2004, Gastroenterology.

[84]  Y. Ben-Neriah,et al.  NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.

[85]  M. Clarke,et al.  Self-renewal and solid tumor stem cells , 2004, Oncogene.

[86]  G. Schweizer-Groyer,et al.  An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. , 2004, Biochemical pharmacology.

[87]  Xiang Ding,et al.  ADAM17 mRNA expression and pathological features of hepatocellular carcinoma. , 2004, World journal of gastroenterology.

[88]  S. Thorgeirsson,et al.  Disregulation of E-cadherin in transgenic mouse models of liver cancer , 2004, Laboratory Investigation.

[89]  Y. Yarden,et al.  Oncogenic growth factor receptors: implications for signal transduction therapy. , 2004, Seminars in cancer biology.

[90]  M. Manns,et al.  Telomeres and telomerase: A dual role in hepatocarcinogenesis , 2004, Hepatology.

[91]  K. Uematsu,et al.  An Anti-Wnt-2 Monoclonal Antibody Induces Apoptosis in Malignant Melanoma Cells and Inhibits Tumor Growth , 2004, Cancer Research.

[92]  J. Furuse,et al.  A phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  T. Fujii,et al.  Focal adhesion kinase is overexpressed in hepatocellular carcinoma and can be served as an independent prognostic factor. , 2004, Journal of hepatology.

[94]  J. Prieto,et al.  Gene therapy of liver diseases , 2004, Expert opinion on biological therapy.

[95]  T. Mak,et al.  Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. , 2004, The Journal of clinical investigation.

[96]  S. S. Koh,et al.  Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma. , 2004, Hepatology research : the official journal of the Japan Society of Hepatology.

[97]  Lieping Chen,et al.  Improving efficacy of interleukin‐12‐transfected dendritic cells injected into murine colon cancer with anti‐CD137 monoclonal antibodies and alloantigens , 2004, International journal of cancer.

[98]  F. Izzo,et al.  Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  C. Qian,et al.  An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice , 2004, Hepatology.

[100]  J. Adams.  The development of proteasome inhibitors as anticancer drugs. , 2004, Cancer cell.

[101]  John Ellis,et al.  Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  J. Prieto,et al.  Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  Y. Maehara,et al.  Role of Expression of Focal Adhesion Kinase in Progression of Hepatocellular Carcinoma , 2004, Clinical Cancer Research.

[104]  R. Foisner,et al.  β-Catenin and TGFβ signalling cooperate to maintain a mesenchymal phenotype after FosER-induced epithelial to mesenchymal transition , 2004, Oncogene.

[105]  A. Datta,et al.  Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. , 2004, Genes & development.

[106]  R. Nusse,et al.  Convergence of Wnt, ß-Catenin, and Cadherin Pathways , 2004, Science.

[107]  M. Lung,et al.  Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line , 2004, Cancer Chemotherapy and Pharmacology.

[108]  C. Schmidt,et al.  Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma. , 2004, Journal of the American College of Surgeons.

[109]  B. Murphy,et al.  Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity , 2004, Cancer Gene Therapy.

[110]  C. Qian,et al.  A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent , 2004, Oncogene.

[111]  F. Eskens,et al.  Angiogenesis inhibitors in clinical development; where are we now and where are we going? , 2004, British Journal of Cancer.

[112]  Frank Petersen,et al.  Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex , 2004 .

[113]  D. Stupack,et al.  Integrins and angiogenesis. , 2004, Current topics in developmental biology.

[114]  G. Dranoff,et al.  Cytokines in cancer pathogenesis and cancer therapy , 2004, Nature Reviews Cancer.

[115]  A. Padhy,et al.  Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[116]  J. Su,et al.  Transforming growth factor-beta1 stimulated protein kinase B serine-473 and focal adhesion kinase tyrosine phosphorylation dependent on cell adhesion in human hepatocellular carcinoma SMMC-7721 cells. , 2003, Biochemical and biophysical research communications.

[117]  Jean Paul Thiery,et al.  Epithelial-mesenchymal transitions in development and pathologies. , 2003, Current opinion in cell biology.

[118]  Y. Matsuzawa,et al.  Expression of ephrin-B1 in hepatocellular carcinoma: possible involvement in neovascularization. , 2003, Journal of hepatology.

[119]  M. Matsuda,et al.  Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis , 2003, International journal of cancer.

[120]  A. García-Sastre,et al.  Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immune-competent mice. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[121]  W. Coleman,et al.  Mechanisms of human hepatocarcinogenesis. , 2003, Current molecular medicine.

[122]  J. Prieto,et al.  Gene therapy of cancer with interleukin-12. , 2003, Current pharmaceutical design.

[123]  D. Schuppan,et al.  Integrin‐mediated control of cell growth , 2003, Hepatology.

[124]  S. Woo,et al.  Telomerase-dependent oncolytic adenovirus for cancer treatment , 2003, Gene Therapy.

[125]  H. Zhang,et al.  Mechanism of β1‐integrin–mediated hepatoma cell growth involves p27 and S‐phase kinase–associated protein 2 , 2003, Hepatology.

[126]  J. Prieto,et al.  Suppression of angiogenesis and tumor growth by adenoviral-mediated gene transfer of pigment epithelium-derived factor. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[127]  J. Prieto,et al.  Pancreatic cancer escape variants that evade immunogene therapy through loss of sensitivity to IFNγ-induced apoptosis , 2003, Gene Therapy.

[128]  J. Prieto,et al.  Expression of Wilms' tumor suppressor in the liver with cirrhosis: Relation to hepatocyte nuclear factor 4 and hepatocellular function , 2003, Hepatology.

[129]  Hans Clevers,et al.  Caught up in a Wnt storm: Wnt signaling in cancer. , 2003, Biochimica et biophysica acta.

[130]  J. Bristol,et al.  In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[131]  G. Mills,et al.  Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors , 2003, Oncogene.

[132]  M. Tai,et al.  Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma , 2003, Cancer.

[133]  J. Prieto,et al.  A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury. , 2003, Cytokine.

[134]  H. Wallace,et al.  Polyamine analogues as anticancer drugs. , 2003, Biochemical Society transactions.

[135]  J. Prieto,et al.  Liver failure caused by herpes simplex virus thymidine kinase plus ganciclovir therapy is associated with mitochondrial dysfunction and mitochondrial DNA depletion. , 2003, Human gene therapy.

[136]  F. McCormick,et al.  Cancer Specific Viruses and the Development of ONYX-015 , 2003, Cancer biology & therapy.

[137]  Yoshiaki Miyauchi,et al.  Cyclins and cyclin‐dependent kinases: Comparative study of hepatocellular carcinoma versus cirrhosis , 2003, Hepatology.

[138]  W. Jarnagin,et al.  Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection , 2003, Cancer Gene Therapy.

[139]  B. Sangro,et al.  Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. , 2003, Current gene therapy.

[140]  J. Folkman.  Antiangiogenic Activity of a Matrix Protein , 2003, Cancer biology & therapy.

[141]  T. Roskams,et al.  Hepatic progenitor cells in human liver diseases. , 2002, Seminars in cell & developmental biology.

[142]  S. Sell.  Cellular origin of hepatocellular carcinomas. , 2002, Seminars in cell & developmental biology.

[143]  J. Prieto,et al.  A novel strategy for the generation of angiostatic kringle regions from a precursor derived from plasminogen , 2002, Gene Therapy.

[144]  Hao Zhang,et al.  β1‐integrin protects hepatoma cells from chemotherapy induced apoptosis via a mitogen‐activated protein kinase dependent pathway , 2002 .

[145]  M. Fiorentino,et al.  Expression, regulation, and function of αV integrins in hepatocellular carcinoma: An in vivo and in vitro study , 2002 .

[146]  M. Manns,et al.  Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induces regression of liver tumors. , 2002, Gastroenterology.

[147]  J. Prieto,et al.  New strategies to enhance gene therapy efficiency. , 2002, Gastroenterology.

[148]  S. Thorgeirsson,et al.  Molecular pathogenesis of human hepatocellular carcinoma , 2002, Nature Genetics.

[149]  R. Warren,et al.  Liver-directed viral therapy for cancer p53-targeted adenoviruses and beyond. , 2002, Surgical oncology clinics of North America.

[150]  E. Biondi,et al.  Ultra-Low-Dose Interleukin-2 in Unresectable Hepatocellular Carcinoma , 2002, American journal of clinical oncology.

[151]  M. Feitelson,et al.  Genetic mechanisms of hepatocarcinogenesis , 2002, Oncogene.

[152]  K. Hu.  Rationale and feasibility of chemoprovention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors. , 2002, The Journal of laboratory and clinical medicine.

[153]  P. Seth,et al.  Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma , 2002, Cancer Gene Therapy.

[154]  J. Prieto,et al.  Cytokine gene transfer into dendritic cells for cancer treatment. , 2002, Current gene therapy.

[155]  D. Bissell.  Chronic liver injury, TGF-β, and cancer , 2001, Experimental & Molecular Medicine.

[156]  Y. Yarden.  The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. , 2001, European journal of cancer.

[157]  W. Greenhalf,et al.  Hepatic intra-arterial delivery of a retroviral vector expressing the cytosine deaminase gene, controlled by the CEA promoter and intraperitoneal treatment with 5-fluorocytosine suppresses growth of colorectal liver metastases , 2001, Gene Therapy.

[158]  V. Carloni,et al.  The integrin, α6β1, is necessary for the matrix‐dependent activation of FAK and MAP kinase and the migration of human hepatocarcinoma cells , 2001 .

[159]  S. Fan,et al.  β‐catenin mutation and overexpression in hepatocellular carcinoma , 2001 .

[160]  J. Prieto,et al.  Adenovirus‐mediated CD40 ligand gene therapy in a rat model of orthotopic hepatocellular carcinoma , 2001, Hepatology.

[161]  D. Kirn.  Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of Phase I and II trials , 2001, Expert opinion on biological therapy.

[162]  D. Stolz,et al.  Changes in WNT/β‐catenin pathway during regulated growth in rat liver regeneration , 2001 .

[163]  B. Pützer,et al.  Large nontransplanted hepatocellular carcinoma in woodchucks: treatment with adenovirus-mediated delivery of interleukin 12/B7.1 genes. , 2001, Journal of the National Cancer Institute.

[164]  M. Kelly,et al.  E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. , 2001, Human gene therapy.

[165]  F. Bertrand,et al.  Insulin and IGF-1 stimulate the β-catenin pathway through two signalling cascades involving GSK-3β inhibition and Ras activation , 2001, Oncogene.

[166]  J. Prieto,et al.  Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12 , 2001 .

[167]  E. Pasquale,et al.  The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization , 2000, Oncogene.

[168]  Shelly C. Lu,et al.  Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. , 2000, Journal of hepatology.

[169]  J. Allison,et al.  Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[170]  Yasuo Ohashi,et al.  Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial , 2000, The Lancet.

[171]  Y. Chung,et al.  Expression of transforming growth factor‐α mRNA in livers of patients with chronic viral hepatitis and hepatocellular carcinoma , 2000 .

[172]  M. Buendia.  Genetics of hepatocellular carcinoma. , 2000, Seminars in cancer biology.

[173]  G. Gores,et al.  Apoptosis and liver disease. , 2000, The American journal of medicine.

[174]  J. Prieto,et al.  Intratumoral Coinjection of Two Adenoviruses, One Encoding the Chemokine IFN-γ-Inducible Protein-10 and Another Encoding IL-12, Results in Marked Antitumoral Synergy1 , 2000, The Journal of Immunology.

[175]  A. Beaudet,et al.  Toxicity Associated with Repeated Administration of First-Generation Adenovirus Vectors Does Not Occur with a Helper-Dependent Vector , 2000, Molecular medicine.

[176]  J. Wands,et al.  Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the escherichia coli purine nucleoside phosphorylase gene , 2000, Hepatology.

[177]  J. Prieto,et al.  Combined gene therapy with suicide gene and interleukin-12 is more efficient than therapy with one gene alone in a murine model of hepatocellular carcinoma. , 2000, Journal of hepatology.

[178]  Katsuhiko Itoh,et al.  Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas , 2000, Nature Medicine.

[179]  J. Prieto,et al.  Adenoviral gene transfer of interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level. , 2000, Human gene therapy.

[180]  F. Garrido,et al.  The HLA crossroad in tumor immunology. , 2000, Human immunology.

[181]  J. Prieto,et al.  Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas , 1999, Gene Therapy.

[182]  H. Kawasaki,et al.  Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. , 1999, Liver.

[183]  K. Stuart,et al.  A Phase II trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma , 1999, Cancer.

[184]  J. Bruix,et al.  Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials , 1999, Hepatology.

[185]  D. Israeli,et al.  p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs , 1998, The Journal of experimental medicine.

[186]  I. Bilbao,et al.  Prognosis of hepatocellular carcinoma in relation to treatment: a multivariate analysis of 178 patients from a single European institution. , 1998, Surgery.

[187]  M. Dewhirst,et al.  Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[188]  K.,et al.  Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[189]  P. Opolon,et al.  Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[190]  K. Matsumoto,et al.  pp60c‐src Activation in hepatocellular carcinoma of humans and LEC rats , 1998, Hepatology.

[191]  Yue Xiong,et al.  ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways , 1998, Cell.

[192]  G. Trinchieri.  Interleukin-12: a cytokine at the interface of inflammation and immunity. , 1998, Advances in immunology.

[193]  R. Lee,et al.  Large cell change (liver cell dysplasia) and hepatocellular carcinoma in cirrhosis: Matched case‐control study, pathological analysis, and pathogenetic hypothesis , 1997, Hepatology.

[194]  D. Guyader,et al.  Prospective randomized trial of chemoembolization versus intra‐arterial injection of 131I‐labeled–iodized oil in the treatment of hepatocellular carcinoma , 1997, Hepatology.

[195]  D. Klatzmann,et al.  A "distant" bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor. , 1997, Human gene therapy.

[196]  Jörg Stappert,et al.  β‐catenin is a target for the ubiquitin–proteasome pathway , 1997 .

[197]  P. Galle,et al.  Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion? , 1996, Nature Medicine.

[198]  J. Coursen,et al.  Tissue‐specific growth suppression and chemosensitivity promotion in human hepatocellular carcinoma cells by retroviral‐mediated transfer of the wild‐type p53 gene , 1996, Hepatology.

[199]  R. Crystal,et al.  Regional delivery of an adenovirus vector containing the Escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver. , 1996, Human gene therapy.

[200]  A. Angiolillo,et al.  Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. , 1996, Blood.

[201]  D. Morgan,et al.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in Patients with Liver Disease , 1995, Clinical pharmacokinetics.

[202]  P. Bedossa,et al.  Transforming growth factor—beta 1 (TGF‐β1) and TGF‐β1 receptors in normal, cirrhotic, and neoplastic human livers , 1995, Hepatology.

[203]  Y. Matsuzawa,et al.  Expression of heparin-binding epidermal growth factor in human hepatocellular carcinoma. , 1994, Gastroenterology.

[204]  B. Sangro,et al.  Partial splenic embolization for the treatment of hypersplenism in cirrhosis , 1993, Hepatology.

[205]  A. Chow,et al.  Recombinant interferon‐α in inoperable hepatocellular carcinoma: A randomized controlled trial , 1993 .

[206]  M. Gerretsen,et al.  A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group. , 1990, British Journal of Cancer.

[207]  Fulvio Mavilio,et al.  Gene therapy , 1993, Nature.

[208]  Richard O. Hynes,et al.  Integrins: Versatility, modulation, and signaling in cell adhesion , 1992, Cell.

[209]  M. Abe,et al.  Cytokine , 2020, Bone Marrow Transplantation.

[210]  P. Sperryn,et al.  Blood. , 1989, British journal of sports medicine.

[211]  I. Forgacs.  GASTROENTEROLOGY , 1988, The Lancet.

[212]  T. Espevik,et al.  Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha , 1987, The Journal of experimental medicine.

[213]  K. Hagino-Yamagishi,et al.  [Oncogene]. , 2019, Gan to kagaku ryoho. Cancer & chemotherapy.

[214]  A. Chadli.  THE CANCER CELL , 1924, La Presse medicale.

[215]  W. Gardner,et al.  Carcinogenesis , 1961, The Yale Journal of Biology and Medicine.

[216]  W. M. Barclay.  Surgery , 1894, Bristol medico-chirurgical journal.